Foghorn Therapeutics (FHTX) Income from Continuing Operations (2019 - 2026)
Foghorn Therapeutics (FHTX) posted quarterly Income from Continuing Operations of 80642000.0 for Q1 2026, down 250.88% year-over-year from 53448929.69 in Q1 2025, and down 238.14% quarter-over-quarter from 23849000.0 in Q4 2025.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 80642000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 250.88% year-over-year to 80642000.0; the TTM figure through Mar 2026 stood at 226030000.0 (down 167.22% YoY), while the FY2025 annual figure was 265279000.0, down 206.26% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 80642000.0, down from 23849000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 14345000.0 in Q3 2023, with the low at 80642000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 25769000.0 (2022), against an average of 31937705.88.
- The sharpest annual moves came in 2022 and 2026: Income from Continuing Operations jumped 74.31% in 2022, then plunged 250.88% in 2026.
- Foghorn Therapeutics' Income from Continuing Operations stood at 28886000.0 in 2022, then climbed by 16.55% to 24106000.0 in 2023, then advanced by 19.09% to 19503000.0 in 2024, then slipped by 22.28% to 23849000.0 in 2025, then plunged by 238.14% to 80642000.0 in 2026.
- Business Quant data shows FHTX's Income from Continuing Operations at 80642000.0 in Q1 2026, 23849000.0 in Q4 2025, and 41751000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Foghorn Therapeutics | 347.14 Mn | 279.06 Mn | - | -7.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.20 Mn |
| Mar 31, 2026 | -19.83 Mn |
| Dec 31, 2025 | -22.17 Mn |
| Sep 30, 2025 | -16.47 Mn |
| Jun 30, 2025 | -18.79 Mn |
| Mar 31, 2025 | -20.22 Mn |
| Dec 31, 2024 | -19.50 Mn |
| Sep 30, 2024 | -19.12 Mn |
| Jun 30, 2024 | -22.98 Mn |
| Mar 31, 2024 | -25.02 Mn |
| Dec 31, 2023 | -24.11 Mn |
| Sep 30, 2023 | -14.35 Mn |
| Jun 30, 2023 | -29.49 Mn |
| Mar 31, 2023 | -30.49 Mn |
| Dec 31, 2022 | -28.89 Mn |
| Sep 30, 2022 | -25.77 Mn |
| Jun 30, 2022 | -27.31 Mn |
| Mar 31, 2022 | -26.91 Mn |
| Dec 31, 2021 | -28.51 Mn |
| Sep 30, 2021 | -26.76 Mn |